Konference: 2010 35th Congress ESMO – účast ČR
Kategorie: Zhoubné nádory prsu
Téma: Breast Cancer, Advanced
Číslo abstraktu: 0297P
Methods: This was a prospective non-interventional study to determine factors associated with the choice of taxane-based trt in pts with advanced BC pre-treated with anthracyclines unless contra-indicated. Patient characteristics were analysed using descriptive statistics. Progression-free survival (PFS) was estimated by the Kaplan-Meier method.
Results: 465 pts prescribed first-line trt were eligible for analysis. Among them there were 104 HER2+ patients with median age of 53 years (in scope of this abstract). ECOG performance status (PS) was 0-1 in 88.5% and hormonal receptors status was positive (HR+) in 50.0% of pts. Median disease free interval (DFI) was 25.5 months (mo). 91.3% had metastatic breast cancer (MBC) and 61.5% of pts had visceral metastases. No patients had received trastuzumab as adjuvant treatment. Trastuzumab in combination with taxane was prescribed in only 61 pts (59%): 47 pts (45%) without other cytotoxic and 14 pts (13%) in combination with other cytotoxic agents. 11 pts (11%) were assigned to trt with single-agent taxane. PFS results for different treatment options are presented in the table.
|Trt options||No. of||PFS, mo|
|All HER2-positive pts||104|
|Trastuzumab trt||61||19.7||(9.3, unest.)|
|Non-trastuzumab trt||41||7.9||(5.0 to 19.2)|
|- Taxane combinationCT||30||18.8||(5.0 to 22)|
|- Taxane monotherapy||11||6.1||(3.8 to 13.3)|
|CT = chemotherapy, PFS =|
Conclusions: Patient with HER2+ advanced breast cancer may not receive anti-HER2 trt in practice. These results suggest that taxane-combination chemotherapy might be a trt option for this population. Further studies are warranted to understand the potential hurdles for use of anti-HER2 trt and to define the best trt strategy for this population. Funding: Study B9E-VI-B007 was sponsored by Eli Lilly.
Disclosure: A. Kral, S. Weitckus and V. Soldatenkova: Employee of Eli Lilly; K. Benhadji: Lilly employment and stock ownership. All other authors have declared no conflicts of interest.
Datum přednesení příspěvku: 10. 9. 2010